このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

HBM Holdings マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Jingsong Wang

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	55.8%
CEO在任期間	8yrs
CEOの所有権	8.4%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	3.9yrs

経営陣の近況

Recent updates

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10

CEO報酬分析

HBM Holdings の収益と比較して、Jingsong Wang の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	US$2m	US$885k	US$23m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	US$2m	US$781k	-US$137m
Sep 30 2022	n/a	n/a	-US$143m
Jun 30 2022	n/a	n/a	-US$149m
Mar 31 2022	n/a	n/a	-US$144m
Dec 31 2021	US$13m	US$13m	-US$138m
Sep 30 2021	n/a	n/a	-US$224m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$303m
Dec 31 2020	US$21m	US$654k	-US$296m

報酬と市場: Jingsongの総報酬 ($USD 1.59M ) は、 Hong Kong市場 ($USD 233.10K ) の同規模の企業の平均を上回っています。

報酬と収益: Jingsongの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jingsong Wang (59 yo)

8yrs

在職期間

US$1,585,000

報酬

Dr. Jingsong Wang M.D., Ph D., serves as Chairman of Board of Directors of HBM Alpha Therapeutics, Inc. He has been Chief Executive Officer of HBM Holdings Limited and Harbour BioMed Shanghai Co., Ltd. sin...

取締役

名称	ポジション	在職期間	報酬	所有権
Jingsong Wang	Founder	8yrs	US$1.59m	8.43% $ 84.6m
Yiping Rong	Chief Scientific Officer & Executive Director	2.2yrs	US$547.00k	0.028% $ 279.5k
Peter Moesta	Member of Scientific Advisory Board & Chief CMC Advisor	no data	データなし	データなし
Robert Kamen	Independent Non-Executive Director & Member of Scientific Advisory Board	7.6yrs	US$50.00k	0.36% $ 3.6m
Albert R. Collinson	Independent Non-Executive Director	less than a year	US$21.00k	データなし
Alexander A. Zukiwski	Member of Scientific Advisory Board	2.2yrs	データなし	データなし
Xiaoping Ye	Independent Non-Executive Director	3.7yrs	US$50.00k	データなし
Jon Marc Wigginton	Member of Scientific Advisory Board	4.1yrs	データなし	データなし
Robert Kramer	Member of Scientific Advisory Board	7.6yrs	データなし	データなし
Frank Grosveld	Member of Scientific Advisory Board	7.6yrs	データなし	データなし
Weiwei Chen	Senior Business Adviser & Non-Executive Director	3.7yrs	US$50.00k	データなし
Zhigang Tian	Member of Scientific Advisory Board	3.9yrs	データなし	データなし

3.9yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: 2142の取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

HBM Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

HBM Holdings Limited Announces Executive Changes

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

HBM Holdings Limited Announces Board Changes

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Less than half of directors are independent

Recent updates

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 17%

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited, Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$0.19 loss in FY 2022)

HBM Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S

HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

HBM Holdings Limited Announces Executive Changes

New major risk - Revenue and earnings growth

Forecast to breakeven in 2023

Consensus EPS estimates upgraded to US$0.05 loss

First half 2023 earnings released: EPS: US$0.004 (vs US$0.10 loss in 1H 2022)

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

HBM Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director

New minor risk - Share price stability

HBM Holdings Limited Announces Board Changes

National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG

HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 (HHLA2) Antibody HBM1020

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Consensus revenue estimates increase by 28%

Consensus estimates of losses per share improve by 36%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Hbm Holdings Limited Announces Food and Drug Administration of the United States Investigational New Drug Clearance for HBM1020 Clinical Trial Initiation

Hbm Holdings Limited Announces Results from Phase I Clinical Trial of Porustobart (Hbm4003)In Combination with Toripalimab in Advanced Melanoma

WuXi Vaccines (Hong Kong) Limited entered into an agreement to acquire Manufacturing facility in Suzhou from HBM Holdings Limited (SEHK:2142).

Less than half of directors are independent

HBM Holdings Limited Appoints Mr. Weihao Xu as Chief Business Officer

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Hbm Holdings Limited Announces Closing the Study of Phase III Clinical Trial of Tanfanercept (Hbm9036)

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Consensus forecasts updated

First half 2022 earnings released: US$0.10 loss per share (vs US$0.084 loss in 1H 2021)

Hbm Holdings Limited Announces Completion of First Dosing of Last Patient with Hbm4003 Phase Ib Trial

Harbour BioMed Announces the Preclinical Results of Porustobart

HBM Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

HBM Holdings Limited Announces IND Approval for Commencement of Phase I Trial of B7H4X4-1BB Bispecific Antibody in China

Hbm Holdings Limited Announces Data Release of Next-Gen Ctla-4 Antibody At Asco 2022

HBM Holdings Limited Announces That Dosing of First Patient in Phase I Trial of B7h4x4-1Bb Bispecific Antibody Hbm7008 Has Been Completed

Consensus forecasts updated

Hbm Holdings Limited Announces Data Release Forecast of Hbm4003 At ASCO 2022

HBM Holdings Limited Announces Board Changes

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

Less than half of directors are independent

Harbour BioMed Appoints Humphrey Gardner as Chief Medical Officer

Consensus revenue estimates increase by 302%

Harbour BioMed Announces Approval for Phase I Trial of B7H4x4-1BB Bispecific Antibody in Australia

HBM Holdings Limited Announces Approval of Investigational New Drug Application for HBM9378 by National Medical Products Administration of the People's Republic of China

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings Limited Announces Completion of First Interim Analysis of Phase III Clinical Trial of Tanfanercept (HBM9036)

Founder recently bought HK$1.0m worth of stock

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Two HBM4003 Phase I Trials

HBM Holdings Limited Announces Completion of First Dosing of First Patient with Batoclimab (Hbm9161) Phase III Trial for Treatment of Generalized Myasthenia Gravis

Harbour Biomed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

HBM Holdings Limited Announces Chinese Regulatory Approval of Two Ind Applications for Next-Generation Anti-Ctla-4 Antibody Hbm4003

First half 2021 earnings released: US$0.084 loss per share (vs US$0.39 loss in 1H 2020)

HBM Holdings Limited Receives National Medical Products Administration of the People's Republic of China Approval of Investigational New Drug Application to Begin Phase II Clinical Trial of HBM9161 in Chronic Inflammatory Demyelinating Polyneuropathy

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

HBM Holdings Limited Provides Update on Ongoing Clinical Studies Forbatoclimab (HBM9161)

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Executive Director, Chief Strategy Officer & Head of U.S. Operations has left the company

マネジメント基準チェック /24